The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Weissenbacher–Zweymuller syndrome (WZS), also called Pierre-Robin syndrome with fetal chondrodysplasia, is an autosomal recessive congenital disorder, linked to mutations (955 gly -> glu) in the COL11A2 gene (located on chromosomal position 6p21.3), which codes for the α2 strand of collagen type XI. It is a collagenopathy, types II and XI disorder. The condition was first characterized in 1964 by G. Weissenbacher and Ernst Zweymüller.
After harnessing fire, humans discovered other forms of energy. The earliest known use of wind power is the sailing ship; the earliest record of a ship under sail is that of a Nile boat dating to around 7,000 BCE. From prehistoric times, Egyptians likely used the power of the annual flooding of the Nile to irrigate their lands, gradually learning to regulate much of it through purposely built irrigation channels and "catch" basins. The ancient Sumerians in Mesopotamia used a complex system of canals and levees to divert water from the Tigris and Euphrates rivers for irrigation. Archaeologists estimate that the wheel was invented independently and concurrently in Mesopotamia (in present-day Iraq), the Northern Caucasus (Maykop culture), and Central Europe. Time estimates range from 5,500 to 3,000 BCE, with most experts putting it closer to 4,000 BCE. The oldest artifacts with drawings depicting wheeled carts date from about 3,500 BCE. More recently, the oldest-known wooden wheel in the world as of 2024 was found in the Ljubljana Marsh of Slovenia; Austrian experts have established that the wheel is between 5,100 and 5,350 years old. The invention of the wheel revolutionized trade and war. It did not take long to discover that wheeled wagons could be used to carry heavy loads. The ancient Sumerians used a potter's wheel and may have invented it. A stone pottery wheel found in the city-state of Ur dates to around 3,429 BCE, and even older fragments of wheel-thrown pottery have been found in the same area.
Porous silicon (abbreviated as "PS" or "pSi") is a form of the chemical element silicon that has introduced nanopores in its microstructure, rendering a large surface to volume ratio in the order of 500 m2/cm3.
Sources: en.wikipedia.org
=== United States === Cannabis tea is scheduled at the federal level in the United States by nature of being a derivative of Cannabis sativa, and it is therefore illegal to possess, buy, and sell. Due to variances in statewide laws, and the reluctance of the federal government to overrule the states, however, the federal legislation has little impact on nationwide use, and is "generally applied only against persons who possess, cultivate, or distribute large quantities of cannabis". As such, regulation of recreational and/or medicinal growth and use on an individual level is not the responsibility of the federal government.
The absence of the thyroid hormones T3 and T4 are responsible for many bodily functions at the genetic and cellular level and an absence of these thyroid hormones as seen in myxedema coma has very serious consequences including a broad spectrum of symptoms and a high mortality rate.
A Pakistani newspaper, citing military sources, reported that seven TTP hideouts in Nangarhar, Paktika, and Khost provinces were destroyed and that more than 80 militants were killed; however, Taliban officials only reported airstrikes in the Nangarhar and Paktika provinces, adding that an airstrike in Bihsud District killed 18 civilians, including 11 children. Taliban officials condemned the airstrikes and warned of a calculated response at an appropriate time. Shayesteh Jan Ahadi, former head of the Paktia Provincial Council, stated that Pakistani airstrikes in several districts were very widespread and powerful. The United Nations Assistance Mission in Afghanistan (UNAMA) reported that Pakistan carried out airstrikes between 11:45 p.m. on 21 February and 12:15 a.m. on 22 February. UNAMA also reported that airstrikes in Paktika province damaged or destroyed infrastructure. On 23 February, UNAMA confirmed that over 13 civilians had been killed by the Pakistani airstrikes, with an additional seven injured. Pakistan described the operation as a retributive response to a series of suicide bombings inside Pakistan, including the 6 February bombing of a Shia mosque in Islamabad that killed 31 worshippers (claimed by ISIS–K), and attacks in Bajaur and Bannu districts in Khyber Pakhtunkhwa during the early days of Ramadan. Pakistan also claimed that the strikes were "intelligence-based, selective operations" against seven camps and hideouts belonging to the Tehreek-e-Taliban Pakistan (TTP), its affiliates, and the Islamic State – Khorasan Province (ISKP).
== Description and conceptual basis == Writing for Science-Based Medicine, Harriet Hall described myofascial release as an umbrella term for several types of physical manipulation, which might more simply be described as a kind of massage based on vaguely defined scientific notions.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.